Oncology and Hematology

Episodes 33-48 of 463

Addressing Psychological Distress in Lung Cancer: The Emerging Role of EMDR Therapy
Addressing Psychological Distress in Lung Cancer: The Emerging Role of EMDR Therapy
Project Oncology®
Addressing Psychological Distress in Lung Cancer: The Emerging Role of EMDR Therapy
Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
Project Oncology®
Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
CME/CE
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
0.25 credits
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Christophe Le Tourneau, MD, PhD
0.25 credits
Long-Term Survival Data in High-Risk NSCLC: Insights from Real-World Practice
Long-Term Survival Data in High-Risk NSCLC: Insights from Real-World Practice
Project Oncology®
Long-Term Survival Data in High-Risk NSCLC: Insights from Real-World Practice
- Jacob Sands, MD
- Joshua K. Sabari, MD
Durable Outcomes in NSCLC: 6-Year Survival Findings from CheckMate 9LA
Durable Outcomes in NSCLC: 6-Year Survival Findings from CheckMate 9LA
Project Oncology®
Durable Outcomes in NSCLC: 6-Year Survival Findings from CheckMate 9LA
- Jacob Sands, MD
- Sandip Patel, MD
6-Year Outcomes from CheckMate 9LA: Efficacy and Safety Across NSCLC Subgroups
6-Year Outcomes from CheckMate 9LA: Efficacy and Safety Across NSCLC Subgroups
Project Oncology®
6-Year Outcomes from CheckMate 9LA: Efficacy and Safety Across NSCLC Subgroups
- Jacob Sands, MD
- Millie Das, MD
Expanding Cancer Detection: How MCED Testing Complements Standard Screening
Expanding Cancer Detection: How MCED Testing Complements Standard Screening
Project Oncology®
Expanding Cancer Detection: How MCED Testing Complements Standard Screening
- Jennifer Caudle, DO
- Patrick McGill, MD
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Project Oncology®
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
- Charles Turck, PharmD, BCPS, BCCCP
- Evandro Bezerra, MD
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Project Oncology®
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
- Charles Turck, PharmD, BCPS, BCCCP
- Evandro Bezerra, MD
Mutational Complexity in ROS1-Positive mNSCLC: Insights from Real-World Practice
Mutational Complexity in ROS1-Positive mNSCLC: Insights from Real-World Practice
Project Oncology®
Mutational Complexity in ROS1-Positive mNSCLC: Insights from Real-World Practice
Immunotherapy Advances in Squamous Cell Anal Carcinoma: A New Standard of Care
Immunotherapy Advances in Squamous Cell Anal Carcinoma: A New Standard of Care
Project Oncology®
Immunotherapy Advances in Squamous Cell Anal Carcinoma: A New Standard of Care
- Brian P. McDonough, MD, FAAFP
- Midhun Malla, MD
Integrating MCED Testing in Practice: Best Practices for Enhancing Cancer Screening
Integrating MCED Testing in Practice: Best Practices for Enhancing Cancer Screening
Project Oncology®
Integrating MCED Testing in Practice: Best Practices for Enhancing Cancer Screening
- Brian P. McDonough, MD, FAAFP
- Mylynda Massart, MD, PhD
Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing
Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing
Project Oncology®
Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing
- Brian P. McDonough, MD, FAAFP
- Marie Wood, MD
Postcolonoscopy Colorectal Cancer: Optimizing Quality to Reduce Risk
Postcolonoscopy Colorectal Cancer: Optimizing Quality to Reduce Risk
Clinician's Roundtable
Postcolonoscopy Colorectal Cancer: Optimizing Quality to Reduce Risk
- Aasma Shaukat, MD, MPH
Assessing Nivolumab + Ipilimumab in mNSCLC: 6-Year Outcomes from CheckMate 9LA
Assessing Nivolumab + Ipilimumab in mNSCLC: 6-Year Outcomes from CheckMate 9LA
Project Oncology®
Assessing Nivolumab + Ipilimumab in mNSCLC: 6-Year Outcomes from CheckMate 9LA
- Jacob Sands, MD
- Martin Dietrich, MD, PhD
Blood-Based Screening for Colorectal Cancer: Benefits and Limitations
Blood-Based Screening for Colorectal Cancer: Benefits and Limitations
Clinician's Roundtable
Blood-Based Screening for Colorectal Cancer: Benefits and Limitations
- Aasma Shaukat, MD, MPH